vs
MERIT MEDICAL SYSTEMS INC（MMSI）与Verisk Analytics（VRSK）财务数据对比。点击上方公司名可切换其他公司
Verisk Analytics的季度营收约是MERIT MEDICAL SYSTEMS INC的2.0倍（$778.8M vs $393.9M），Verisk Analytics净利率更高（25.3% vs 9.6%，领先15.7%），MERIT MEDICAL SYSTEMS INC同比增速更快（10.9% vs 5.9%），Verisk Analytics自由现金流更多（$276.1M vs $74.0M），过去两年MERIT MEDICAL SYSTEMS INC的营收复合增速更高（10.3% vs 5.2%）
梅里特医疗系统公司是一家全球性医疗设备企业，设计、生产和销售适用于心脏病学、放射学、肿瘤学、内窥镜及重症监护领域的介入和诊断产品，为全球医院及医疗机构提供微创医疗解决方案，助力提升患者疗效和临床操作效率。
Verisk Analytics是总部位于美国新泽西州泽西市的跨国数据分析与风险评估企业，服务覆盖保险、政府、风险管理等领域，依托自有数据集与行业专业经验，为客户提供反欺诈、精算、保险承保、消防、巨灾与天气风险、数据管理等方向的预测分析及决策支持咨询服务。
MMSI vs VRSK — 直观对比
营收规模更大
VRSK
是对方的2.0倍
$393.9M
营收增速更快
MMSI
高出5.0%
5.9%
净利率更高
VRSK
高出15.7%
9.6%
自由现金流更多
VRSK
多$202.1M
$74.0M
两年增速更快
MMSI
近两年复合增速
5.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $393.9M | $778.8M |
| 净利润 | $38.0M | $197.2M |
| 毛利率 | 49.6% | 69.7% |
| 营业利润率 | 13.8% | 40.3% |
| 净利率 | 9.6% | 25.3% |
| 营收同比 | 10.9% | 5.9% |
| 净利润同比 | 36.0% | -6.3% |
| 每股收益（稀释后） | $0.64 | $1.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MMSIVRSK
| Q4 25 | $393.9M | $778.8M | ||
| Q3 25 | $384.2M | $768.3M | ||
| Q2 25 | $382.5M | $772.6M | ||
| Q1 25 | $355.4M | $753.0M | ||
| Q4 24 | $355.2M | $735.6M | ||
| Q3 24 | $339.8M | $725.3M | ||
| Q2 24 | $338.0M | $716.8M | ||
| Q1 24 | $323.5M | $704.0M |
净利润MMSIVRSK
| Q4 25 | $38.0M | $197.2M | ||
| Q3 25 | $27.8M | $225.5M | ||
| Q2 25 | $32.6M | $253.3M | ||
| Q1 25 | $30.1M | $232.3M | ||
| Q4 24 | $27.9M | $210.4M | ||
| Q3 24 | $28.4M | $220.1M | ||
| Q2 24 | $35.7M | $308.1M | ||
| Q1 24 | $28.2M | $219.6M |
毛利率MMSIVRSK
| Q4 25 | 49.6% | 69.7% | ||
| Q3 25 | 48.5% | 70.1% | ||
| Q2 25 | 48.2% | 70.3% | ||
| Q1 25 | 48.4% | 69.3% | ||
| Q4 24 | 48.7% | 68.7% | ||
| Q3 24 | 46.4% | 69.2% | ||
| Q2 24 | 47.7% | 69.4% | ||
| Q1 24 | 46.9% | 67.6% |
营业利润率MMSIVRSK
| Q4 25 | 13.8% | 40.3% | ||
| Q3 25 | 11.1% | 45.0% | ||
| Q2 25 | 12.3% | 45.9% | ||
| Q1 25 | 11.5% | 43.8% | ||
| Q4 24 | 10.3% | 43.0% | ||
| Q3 24 | 11.0% | 42.9% | ||
| Q2 24 | 13.6% | 44.5% | ||
| Q1 24 | 11.1% | 43.7% |
净利率MMSIVRSK
| Q4 25 | 9.6% | 25.3% | ||
| Q3 25 | 7.2% | 29.4% | ||
| Q2 25 | 8.5% | 32.8% | ||
| Q1 25 | 8.5% | 30.8% | ||
| Q4 24 | 7.9% | 28.6% | ||
| Q3 24 | 8.4% | 30.3% | ||
| Q2 24 | 10.6% | 43.0% | ||
| Q1 24 | 8.7% | 31.2% |
每股收益（稀释后）MMSIVRSK
| Q4 25 | $0.64 | $1.41 | ||
| Q3 25 | $0.46 | $1.61 | ||
| Q2 25 | $0.54 | $1.81 | ||
| Q1 25 | $0.49 | $1.65 | ||
| Q4 24 | $0.46 | $1.50 | ||
| Q3 24 | $0.48 | $1.54 | ||
| Q2 24 | $0.61 | $2.15 | ||
| Q1 24 | $0.48 | $1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $446.4M | $2.2B |
| 总债务越低越好 | $734.0M | $3.2B |
| 股东权益账面价值 | $1.6B | $309.0M |
| 总资产 | $2.7B | $6.2B |
| 负债/权益比越低杠杆越低 | 0.46× | 10.45× |
8季度趋势，按日历期对齐
现金及短期投资MMSIVRSK
| Q4 25 | $446.4M | $2.2B | ||
| Q3 25 | $392.5M | $2.1B | ||
| Q2 25 | $341.8M | $628.7M | ||
| Q1 25 | $395.5M | $1.1B | ||
| Q4 24 | $376.7M | $291.2M | ||
| Q3 24 | $523.1M | $458.0M | ||
| Q2 24 | $636.7M | $632.1M | ||
| Q1 24 | $581.9M | $352.4M |
总债务MMSIVRSK
| Q4 25 | $734.0M | $3.2B | ||
| Q3 25 | $732.9M | $3.2B | ||
| Q2 25 | $731.8M | $3.2B | ||
| Q1 25 | $730.7M | $3.2B | ||
| Q4 24 | $729.6M | $2.5B | ||
| Q3 24 | $750.5M | $2.5B | ||
| Q2 24 | $801.3M | $2.6B | ||
| Q1 24 | $800.1M | $2.9B |
股东权益MMSIVRSK
| Q4 25 | $1.6B | $309.0M | ||
| Q3 25 | $1.5B | $376.7M | ||
| Q2 25 | $1.5B | $311.7M | ||
| Q1 25 | $1.4B | $123.0M | ||
| Q4 24 | $1.4B | $100.1M | ||
| Q3 24 | $1.3B | $299.6M | ||
| Q2 24 | $1.3B | $430.3M | ||
| Q1 24 | $1.2B | $282.2M |
总资产MMSIVRSK
| Q4 25 | $2.7B | $6.2B | ||
| Q3 25 | $2.6B | $6.2B | ||
| Q2 25 | $2.6B | $4.8B | ||
| Q1 25 | $2.5B | $5.1B | ||
| Q4 24 | $2.4B | $4.3B | ||
| Q3 24 | $2.4B | $4.6B | ||
| Q2 24 | $2.4B | $4.8B | ||
| Q1 24 | $2.3B | $4.5B |
负债/权益比MMSIVRSK
| Q4 25 | 0.46× | 10.45× | ||
| Q3 25 | 0.48× | 8.57× | ||
| Q2 25 | 0.49× | 10.37× | ||
| Q1 25 | 0.51× | 26.30× | ||
| Q4 24 | 0.53× | 25.44× | ||
| Q3 24 | 0.57× | 8.50× | ||
| Q2 24 | 0.62× | 5.93× | ||
| Q1 24 | 0.65× | 10.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.5M | $343.3M |
| 自由现金流经营现金流 - 资本支出 | $74.0M | $276.1M |
| 自由现金流率自由现金流/营收 | 18.8% | 35.5% |
| 资本支出强度资本支出/营收 | 6.2% | 8.6% |
| 现金转化率经营现金流/净利润 | 2.59× | 1.74× |
| 过去12个月自由现金流最近4个季度 | $215.7M | $1.2B |
8季度趋势，按日历期对齐
经营现金流MMSIVRSK
| Q4 25 | $98.5M | $343.3M | ||
| Q3 25 | $75.0M | $403.5M | ||
| Q2 25 | $83.3M | $244.5M | ||
| Q1 25 | $40.6M | $444.7M | ||
| Q4 24 | $68.7M | $263.9M | ||
| Q3 24 | $47.3M | $296.2M | ||
| Q2 24 | $68.5M | $211.7M | ||
| Q1 24 | $36.2M | $372.2M |
自由现金流MMSIVRSK
| Q4 25 | $74.0M | $276.1M | ||
| Q3 25 | $52.5M | $336.1M | ||
| Q2 25 | $69.6M | $188.7M | ||
| Q1 25 | $19.5M | $391.0M | ||
| Q4 24 | $65.3M | $208.5M | ||
| Q3 24 | $38.0M | $240.7M | ||
| Q2 24 | $57.9M | $153.9M | ||
| Q1 24 | $24.5M | $317.0M |
自由现金流率MMSIVRSK
| Q4 25 | 18.8% | 35.5% | ||
| Q3 25 | 13.7% | 43.7% | ||
| Q2 25 | 18.2% | 24.4% | ||
| Q1 25 | 5.5% | 51.9% | ||
| Q4 24 | 18.4% | 28.3% | ||
| Q3 24 | 11.2% | 33.2% | ||
| Q2 24 | 17.1% | 21.5% | ||
| Q1 24 | 7.6% | 45.0% |
资本支出强度MMSIVRSK
| Q4 25 | 6.2% | 8.6% | ||
| Q3 25 | 5.8% | 8.8% | ||
| Q2 25 | 3.6% | 7.2% | ||
| Q1 25 | 5.9% | 7.1% | ||
| Q4 24 | 1.0% | 7.5% | ||
| Q3 24 | 2.8% | 7.7% | ||
| Q2 24 | 3.1% | 8.1% | ||
| Q1 24 | 3.6% | 7.8% |
现金转化率MMSIVRSK
| Q4 25 | 2.59× | 1.74× | ||
| Q3 25 | 2.70× | 1.79× | ||
| Q2 25 | 2.56× | 0.97× | ||
| Q1 25 | 1.35× | 1.91× | ||
| Q4 24 | 2.46× | 1.25× | ||
| Q3 24 | 1.66× | 1.35× | ||
| Q2 24 | 1.92× | 0.69× | ||
| Q1 24 | 1.28× | 1.69× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MMSI
| Other | $154.6M | 39% |
| Peripheral Intervention | $93.2M | 24% |
| Cardiac Intervention | $50.2M | 13% |
| OEM | $42.6M | 11% |
| Custom Procedural Solutions | $33.1M | 8% |
| Endoscopy Segment | $20.1M | 5% |
VRSK
暂无分部数据
